RENOWN NEWSROOM

The award is given annually to a member of the Nevada pharmacy community making significant and sustained contributions to the field Kate Ward, Pharm.D., BCPS Director of Clinical Pharmacy at Renown Health is the 2022 recipient of the Nevada Society of Health System Pharmacists (NVSHP) President’s Award. Dr. Ward has been with Renown for over a decade, starting as a Clinical Pharmacist in 2009. As the Director of Clinical Pharmacy, she is responsible for the oversight of all clinical pharmacy activities at Renown Regional, South Meadows and Rehab. Additionally, Dr. Ward is the Residency Director of the Post-Graduate Year 1 (PGY1) Pharmacy Practice Residency at Renown Regional Medical Center. “We are so proud that Kate has been recognized by the Nevada Society of Health System Pharmacists with the President’s Award and for her many accomplishments as a member of our Renown Pharmacy team. With 66% of adults taking five or more drugs per day and 27% taking 10 or more per day, a pharmacist’s review is critical in supporting patient safety and well-being,” says Tom Graf, MD, interim CEO, Renown Health. “Beyond that, pharmacists have the ability to suggest methods for accurately and effectively taking prescribed medications, discuss medication safety, identify and manage side effects and assist patients and families in managing chronic health conditions.” As a licensed pharmacist, Dr. Ward holds The Doctor of Pharmacy degree (abbreviated Pharm.D. or PharmD) from the University of Colorado. The Pharm.D. is a professional degree similar to a Doctor of Medicine (MD) or Doctor of Dental Surgery (DDS). As a doctorate, it represents the increasing responsibility pharmacists have in healthcare systems and the high trust Americans have in pharmacists. The Doctor of Pharmacy degree takes three to four years of undergraduate pre-professional (prerequisite) coursework, followed by four academic years in a professional program. Most students need four years to complete their prerequisite courses. Thus, it usually takes eight years of college study to earn a Pharm.D. and become a pharmacist. Pharmacists working in hospitals and health systems often complete additional post-graduate training after a Pharm.D. degree. Dr. Ward completed a PGY1 Residency at Stanford prior to joining the Pharmacy Department at Renown. “Dr. Ward is such an asset to Renown and our community. Her incredible perseverance to reach for and achieve higher aspirations has resulted in this important recognition by our peers across the state. She consistently contributes her pharmacy expertise to patients, physicians, clinicians and healthcare students and volunteers her time to advance the profession at both the state and national level through pharmacy professional organization participation. It is wonderful to have her efforts recognized by NVSHP,” says Adam Porath, Pharm.D., BCACP, BCPS, FASHP, Vice President, Pharmacy. On Sept. 24, NVSHP and the Nevada Pharmacy Alliance held their annual joint meeting at Renown Regional Medical Center. During this meeting, Dr. Ward was awarded the NVSHP President’s Award. The President’s Award is awarded annually at NVSHP President's discretion to a member making significant and sustained contributions to NVSHP. Dr. Ward was specifically recognized for representing the State of Nevada at the American Society Health System Pharmacists House of Delegates for several consecutive years, as well as her continuous contributions to the annual NVSHP Student Symposium. Established in October 2006, NVSHP has diligently worked on continuing the strong foundation developed to better meet the needs of health-system pharmacists in Nevada. The organization was established on a strong mission statement that enables Nevada's pharmacists to be heard, from all regions of the state and in one collective voice to advocate for patient care. Are you interested in working with this award-winning team? The Renown Health Pharmacy is hiring for multiple roles, including pharmacy technician and clinical pharmacist. For more information, visit careers.renown.org. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 6,500 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in a community-based genetic population health study, the Healthy Nevada Project®.

Read More About Renown's Dr. Kate Ward Honored with Nevada Society of Health System Pharmacists (NVSHP) President's Award

Renown Health team recognized nationally for excellence in health care communications and outreach. Each year, Ragan Communications and PR Daily celebrate the most successful teams in the communication, public relations, marketing and employee wellbeing industries. As the leading voice in organizational communications – both internal and external – Ragan Communications recognizes the industry’s best communications teams. This prestigious award recognizes professional excellence while inspiring and engaging other current and future communicators regarding best practices. This year, Ragan Communications and PR Daily have selected the Marketing, Communications, Patient Experience and Community Outreach Team for Renown Health as “Communications Team of the Year.” In selecting Renown Health for this honor, Ragan judges noted that Renown Health earned its spot as a “Communications Team of the Year” for their communications response to the COVID-19 pandemic and for engaging the community to build a high-quality, trusted and desired health care experience, brand and reputation. Specifically the judged noted that Renown “implemented a Health Incident Command Structure to serve the community, organizing communications resources to mitigate, prepare, respond, communicate and recover from the COVID-19 outbreak and enhancing Renown ‘s capacity to provide access to care. The Renown team also implemented a plan to communicate safety, and prevention messaging, creating and distributing timely, accurate, and relevant communications customized to audience needs to reduce anxiety and maintain Renown’s leadership position for patient safety.” Judges also noted the success of the inspirational brand and messages of the “Fight the Good Fight” campaign, which helped to inspire and motivate a community through a difficult time. Through the pandemic, the Communications team also successfully implemented a new website, renown.org. Over 2.2 million people a year now visit the site to find a doctor by reading honest reviews from certified patients for Renown Medical Group providers, enroll for Hometown Health insurance benefits or seek health information or care. The Renown Health Marketing, Communications, Patient Experience and Community Outreach Team is led by Suzanne Hendery, Cristal Herrera, Emily MacMillan, Whitney Hansen and Annie Zucker and represent professionals with research, digital, web, communications, marketing, outreach, customer service and relationship-building expertise. The team was selected as one of three health care organizations and amid a flood of impressive entrants from all industries including Twitter and 3M. Commenting on the team, Thomas Graf, MD, FAAFP, CEO of Renown Health said, “We are very proud that Renown Health has been honored for excellence in communications. Improving the health and wellness of an entire population of people is a huge task- and it takes all of us, working together, to accomplish great things. We focus on preventing illnesses, and we benefit from a team of professional communicators who believe in- and demonstrate our mission- to keep people healthy, to make healthcare more accessible and affordable, and to achieve the vision of a healthy Nevada.” Renown Health is hiring key roles to support the health and well-being of our community, and encourages those with a passion for service to join the Renown family to Fight the Good Fight. Apply at careers.renown.org. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®.

Read More About Renown Home to "Communications Team of the Year"

Pictured left to right: Erin VanKirk, MSN, RN, Renown Health Director of Nursing Education; Mitch Krebs, Program Director at Helmsley Charitable Trust; Dr. Graf, Renown Health CEO; Greg Walaitis Renown Health Chief Development Officer. Renown Health will use the grant to build the Helmsley Simulation and Innovation Center to improve the health system’s training abilities The Leona M. and Harry B. Helmsley Charitable Trust has granted $3.1 million to Renown Health for construction of a new simulation and innovation center that will greatly expand the health system’s ability to train healthcare providers throughout northern Nevada. The new center will be named the Helmsley Simulation and Innovation Center. Expected to open in April 2023, the center will feature three simulated patient rooms, classroom space, computer labs and a conference center, allowing trainers to run current and future healthcare professionals through real-life acute, outpatient, telemedicine and specialty care scenarios. The new center will let Renown Health train substantially more nurses, physicians, community clinical partners, medical students and rural providers while improving medical and nursing expertise to support staff throughout northern Nevada. “The Helmsley Charitable Trust is excited to fund this new simulation center, which will provide healthcare professionals across rural Nevada with state-of-the-art training in a variety of situations they’ll encounter,” said Walter Panzirer, a trustee of the Helmsley Charitable Trust. “The project fits with our goal to level the playing field by giving rural residents access to top-notch healthcare, regardless of their ZIP code.” “Simulation education has become standard practice for many of our healthcare personnel,” said Erin Van Kirk MSN, RN, Director of Nursing Education. “This lab will provide expanded opportunities in a controlled setting where physicians, nurses, and students can gain valuable experience in providing the best care possible.” Renown Health has outgrown its current simulation lab, which opened in 2016 in Renown Regional Medical Center. The new, larger, state-of-the-art simulation and innovation center will increase Renown Health’s training capacity from 1,500 to 2,500 each year. The new facility will be equipped with state-of-the-art simulation mannequins and other equipment that includes a telemetry monitor, IV and epidural equipment, a code cart, a defibrillator, a balloon pump, ventilators and a cooling machine. The center will also support Renown Health’s recently established partnership with the University of Nevada, Reno School of Medicine, expanding training modules focused on rural health and virtual care through telemedicine. “The facility will help Renown Health respond to our region’s growing population by allowing us to support the training and competency necessary for our care providers to make a genuine difference in the health and well-being of the people and communities we serve,” said Melodie Osborn, RN, MBA, Chief Nursing Executive at Renown Health. “This generous grant for the new simulation and innovation center from the Helmsley Charitable Trust is truly an investment in the bright future we envision for Renown, our care teams and the community.” About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org. About the Helmsley Charitable Trust The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting exceptional efforts in the U.S. and around the world in health and select place-based initiatives. Since beginning active grantmaking in 2008, Helmsley has committed more than $3 billion for a wide range of charitable purposes. Helmsley’s Rural Healthcare Program funds innovative projects that use information technologies to connect rural patients to emergency medical care, bring the latest medical therapies to patients in remote areas, and provide state-of-the-art training for rural hospitals and EMS personnel. To date, this program has awarded more than $500 million to organizations and initiatives in the states of North Dakota, South Dakota, Nebraska, Wyoming, Minnesota, Iowa, Montana, and Nevada. For more information, visit helmsleytrust.org.

Read More About Helmsley Charitable Trust Grants $3.1 Million to Renown Health

“Amazing! Phenomenal! Thank you for always showing genuine concern. You are kind, considerate and caring. You are interested in me. You are the best doctor I have ever had. I trust you with my life. You act on things, right away. You are awesome. You have saved my life, and my family. You are knowledgeable, thorough, intelligent and compassionate. You are my favorite. You are my angel baby. You have made me better. You always make me feel like a success, even if I could have tried harder. I love you. I thank you.” These are some of the comments made by patients regarding their doctors and advanced practice providers honored this morning by Sy Johnson, President and Chief of Staff for Renown Health. In honor of Healthcare Week, Renown Medical Group, the largest medical practice in northern Nevada, honored 46 physicians and advanced practice providers at the Dr. John Spellman Excellence in Patient Communications Award Celebration. This new annual award, supported by the Renown Health Foundation charitable organization and a donor family, honors physicians and advanced practice providers who demonstrate exceptional communications skills in their clinical practice, as awarded by their patients. Recipients of this award are ranked in the top ten percent nationally in provider communication for 2021, as measured by over 11 thousand patients who responded to the Centers for Medicare & Medicaid Services’ (CG-CAPHS) or Clinician and Group Consumer Assessment of Healthcare Providers and Systems patient experience survey between October 2020 and June 2021. Patients were asked if their medical providers explained things in a way they could understand; if they listened carefully; if they showed respect for what they had to say; if they spent enough time with them; if they read their medical records; if they ordered tests and followed up with them on their results; and to give them a rating on a scale of 1 to 10, where 10 was the highest score. “As honorees, your patients have given you a 10, an A+ and you set the gold standard for excellent communications with patients-scoring in the top 10% nationally,” said Rahul Mediwala, MD, Chief Medical Officer for Renown Medical Group. “I love what I do, and it’s wonderful to know that my patients appreciate the care I provide,” said Christina Alsop, DNP, one of the providers honored today. The awards were given in remembrance of Dr. John W. Spellman, human rights advocate, scholar and professor, 7/27/1934 to 6/25/2021 by his family. The Recipients of the 2021 Dr. John Spellman Excellence in Patient Communications Award are: Alsop, Christina Barangan, Caroline J. Basho, Shruti Bloch, Melissa P Bryan, Janice K. Budhecha, Sonia Burgio, Pamela A. Cavin, Lisa C. Dimpel, Ashley J. Dorsa, Denise J. Galanopoulos, Christos A. Galdo, Bella B. Grudzinski, Courtney Dianne Hansen, Benjamin Hardacre, Michael C. Healy, Sara Anne Kermode, Charlotte A. Kiser, Michele J. Klippenstein, Matthew Landis, Philip H. May, Whitney Medina, Mary Beth E. Mindeguia, Catherine E. Miyagawa, Dean Moore, Willa F. Morris, Katelyn Morton, Lillian Nielsen, Lorri Nylk, Janina Park, Susan J. Patel, Bejal Powers, Cindy M. Roumanas, Athan Safdi, Adam Sandefur, Lauren L. Schnell Blitstein, Jamie M. Silverhart, Julie A. Stodtmeister, Russell T. Sutton, Jennifer B. Tay, Jennifer Thyssen, Katherine A. Wagner, Karen Wiese, Matthew C. Wilson, Kristin L, Zucker, Jacob P. Patients served include those at Renown Regional Medical Center, the only Level II Trauma Center between Sacramento and Salt Lake City, and #1 Hospital in the State of Nevada in U.S. News and World Report Best Hospital Rankings for 2021. Physicians and providers also provide services to patients at Renown South Meadows Medical Center, named #1 Best Hospital for 2020 by U.S. News & World Report; and to patients at RenownRehabilitation Hospital, northern Nevada’s only Commission on Accreditation of Rehabilitation Facilities (CARF)- accredited hospital, specializing in the treatment of brain injury, spinal cord injury and stroke. Renown Health is integrated with the University of Nevada, Reno School of Medicine, Nevada’s first medical school, which serves to enhance the health of the community through increased access to care, innovative health care delivery, expansion of clinical research and training for the next generation of physicians and health care professionals. Almost 700 Renown Medical Group primary care and specialty providers are currently accepting new patients and accept most health insurance plans, including Renown’s not-for-profit insurance plan, Hometown Health. To find the doctor or provider that is best for you visit renown.org, or self schedule with your established provider at MyChart or call the Renown Customer Engagement Center at 775-982-4100. Renown Health is currently hiring in all areas. Search for a new career opportunity and apply online at careers.renown.org. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org.

Read More About Honoring Excellence in Patient Communications

Released in partnership with the Desert Research Institute: New research from the Healthy Nevada Project® finds that a confirmed diagnosis does not always result in changes to patient care. Presenting individuals with potentially life-altering health information doesn’t mean the individuals – or their healthcare providers – will act on it. Follow-up education and conversations about actionable care plans with patients and their doctors are key next steps, according to new research from the Healthy Nevada Project.  The Healthy Nevada Project is a genetic screening and research project that launched in 2016 as a partnership between DRI and Renown Health. The project now has more than 50,000 participants, with genetic sequencing provided by Helix.  Between September 2018 and September 2020, the Healthy Nevada Project successfully notified 293 participants that they were genetically at risk for hereditary breast and ovarian cancer syndrome, Lynch syndrome, or familial hypercholesterolemia – three common genetic conditions known collectively as the Centers for Disease Control and Prevention (CDC) Tier 1 conditions. In a study published today in Frontiers in Genetics, Healthy Nevada Project scientists looked at the impact that notifying a patient of a positive finding for a CDC Tier 1 condition had on the care that the patient received in the months and years that followed.  According to their results, among the 293 Healthy Nevada Project participants who were notified of their genetic risk of a CDC Tier 1 condition, 71 percent of participants with electronic health records shared their findings with healthcare providers. However, only 30 percent of the electronic health records for these patients contained documentation of the genetic diagnosis, and only 10 percent of examined patients experienced a possible change in care after receiving the results of their genetic screening.  “The Healthy Nevada Project was implemented with a ‘hands-off’ approach where the participants receive their findings and decide with whom and when to share those findings. The findings were not automatically added to their electronic health records,” said Dr. Gai Elhanan, health data scientist at DRI and co-lead author of the study. “What we’re learning now is that to ensure that important genetic findings are integrated into the care journey it is important to make their inclusion into the electronic health records part of the study.” This study builds on previous Healthy Nevada Project research published in Nature Medicine demonstrating the importance of screening for CDC Tier 1 conditions, which affect about one in 75 individuals and can be mitigated or even prevented from developing into disease when detected early. This study found that as many as 90 percent of the CDC Tier 1 cases are missed by clinical providers during normal clinical care screenings and examinations. During the current study, the Healthy Nevada Project scientists found that 19 percent of studied participants had already developed one of the CDC Tier 1 conditions, and thus would have potentially benefited from earlier notification about their condition. The study team hopes that their findings will encourage individuals in Nevada to obtain genetic testing for these relatively common conditions. Even if individuals are older or have already suffered from diseases related to these conditions, testing could also prove beneficial to siblings, children, and grandchildren who may also be at risk and who could subsequently be screened in the event of a positive finding. The study team also encourages informing health care providers of the importance of incorporating genetic diagnoses into the pharmaceutical (for example, for Familial Hypercholesterolemia) and treatment advice given to patients.  “As a result of this analysis, the clinicians at Renown Health and the Healthy Nevada Project researchers have made significant changes, including obtaining informed consent from participants to report positive findings from their genetics reports directly into their electronic medical record,” said Daniel Kiser, M.S., assistant research scientist of data science at DRI and co-lead author of the study. “This will help both participants, their clinical providers, and the whole state maximize the long-term benefits of the Healthy Nevada Project voluntary population-based genetic screening.” Additional information: The full text of the study,  Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record, is available from Frontiers in Genetics: https://www.frontiersin.org/articles/10.3389/fgene.2022.866169/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Genetics&id=866169.  This project was funded by Renown Health, the Renown Health Foundation, and the Nevada Governor’s Office of Economic Development. Study authors included Gai Elhanan (DRI), Daniel Kiser (DRI), Iva Neveux (DRI), Shaun Dabe (Renown Health), Alexander Bolze (Helix), William Metcalf (DRI), James Lu (Helix), and Joseph Grzymski (DRI/Renown Health). For more information on the Healthy Nevada Project® or to request genetic screening, please visit: https://healthynv.org/ About DRI The Desert Research Institute (DRI) is a recognized world leader in basic and applied environmental research. Committed to scientific excellence and integrity, DRI faculty, students who work alongside them, and staff have developed scientific knowledge and innovative technologies in research projects around the globe. Since 1959, DRI’s research has advanced scientific knowledge on topics ranging from humans’ impact on the environment to the environment’s impact on humans. DRI’s impactful science and inspiring solutions support Nevada’s diverse economy, provide science-based educational opportunities, and inform policymakers, business leaders, and community members. With campuses in Las Vegas and Reno, DRI serves as the non-profit research arm of the Nevada System of Higher Education. For more information, please visit www.dri.edu. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org. About Helix Helix is the leading population genomics and viral surveillance company operating at the intersection of clinical care, research, and data analytics. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision making. Learn more at www.helix.com.

Read More About Study Shows Importance of Ensuring Participant and Provider Follow-up After a Genetic Screening Result

Three-day medical education conference advances research, education, prevention and treatment. Physicians and medical professionals from throughout the Mountain West will soon be convening in Lake Tahoe to explore emerging treatments, the most recent advances and new clinical guidelines for the diagnosis, treatment and prevention of cardiovascular disease, diabetes mellitus, stroke and heart disease. Hosted by Renown's Institute for Heart & Vascular Health and the Nevada Academy of Family Physicians, the three-day Trends in Cardiovascular Medicine conference will bring together national experts to explore challenges and solutions to cardiovascular diseases, the leading cause of death globally, taking an estimated 17.9 million lives each year. "Our mission is to advance health in America. As Nevada's first integrated health system, with our University of Nevada, Reno School of Medicine affiliation, we are advancing health and health care through world-class medical education, clinical research and patient care for our community, our state and our nation," says Anthony D. Slonim, MD, DrPH, President & CEO, Renown Health. "And, we have so much work to do. In 2019, 9.5% of Nevadans reported being told by a health professional that they had angina or coronary heart disease; which is significantly above the national average of 8.4%. As public health and health care providers, we can do more to encourage people to adopt healthy lifestyle habits to keep their heart healthy and help prevent heart disease through the Healthy Nevada Project®, where people can understand their genetic risks at no-cost." "The driving force behind this collaborative event is the shared missions of all our organizations, across the country, to advance progress in cardiovascular research, education, prevention and treatment," says Jayson Morgan, MD, FACC, Director Cardiovascular Services at Renown. "We will be joined by colleagues from Johns Hopkins, Cedars-Sinai, Scripps, University of New Mexico Health Sciences, University of Utah, Medical College of Wisconsin, the Metabolic Institute of America and locally- with experts from Renown's Institute for Heart & Vascular Health/UNR Med, St. Mary's and Barton Health - to discuss contemporary trends in providing excellent cardiovascular care and prevention." New research will be presented each day, including: “Vaping and Electronic Cigarettes – The Hidden Epidemic: What the Clinician Needs to Know” Michael J. Blaha, MD, MPH, FACC, Professor of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Director of Clinical Research, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD “Optimizing Glycemic Control in the Inpatient Setting” Kendall M. Rogers, MD, CPE, FACP, SFHM, Professor, Department of Internal Medicine, University of New Mexico School of Medicine, Chief, Division of Hospital Medicine, Department of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM “Perioperative Medicine Update”                                                                                                                                                                                             Barbara A. Slawski, MD, MS, SFHM Professor of Medicine & Orthopaedic Surgery, Chief, Section of Hospital Medicine, Division of General Internal Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI “Understanding hATTR Amyloidosis: Clinical Presentation and Treatment Landscape” Jignesh K. Patel, MD, PhD, FACC, FRCP, FAST, FAHA, Clinical Professor of Medicine, Medical Director, Heart Transplant Program, Director, Cardiac Amyloid Program, Director, Heart Transplant Research, Cedars-Sinai Medical Center, Los Angeles, CA “Coronary Artery Calcium in 2021: Guideline-Endorsed and Ready for Prime Time” “The Evolving Landscape of Obesity Management – A 2021 Update” Ken Fujioka, MD, Director of the Center for Weight Management, Director of the Nutrition and Metabolic Research Center, Scripps Clinic, Department of Diabetes and Endocrine, San Diego, CA “The Evolving Landscape of Obesity Management – A 2021 Update” Ken Fujioka, MD, Director of the Center for Weight Management, Director of the Nutrition and Metabolic Research Center, Scripps Clinic, Department of Diabetes and Endocrine, San Diego, CA “Management of Atrial Fibrillation: Where We Are; Where We Are Headed” Matthew A. Cain, MD, Electrophysiologist, Renown Institute for Heart & Vascular Health, Renown Medical Group, Reno, NV "The Story of a Murmur” Abhilash Akinapelli, MD, Cardiac Valve & TAVR Program Director, Renown Institute for Heart & Vascular Health, Renown Medical Group, Reno, NV "Update on the Cardiovascular Effects of COVID-19” Siddharth Singh, MD, Assistant Director, Echo Fellowship Training Program, Smidt Heart Institute, Cedars-Sinai, Los Angeles, CA “Antibiotic Stewardship: How to Improve Our Prescribing for Now and Later”                                                                                                                            Valerie M. Vaughn, MD, MSc, FACP, FHM, Assistant Professor, Instructional Track Director of Hospital Medicine Research, Division of General Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT "Emerging Trends in the Clinical Management of VTE”                                                                                                                                                                Victor F. Tapson, MD, FCCP, FRCP, Director, Clinical Research for the Women’s Guild Lung Institute, Director, Venous Thromboembolism & Pulmonary Vascular Disease Research Program, Associate Director, Pulmonary and Critical Care Division, Cedars-Sinai Medical Center, Los Angeles, CA “Contemporary Approach to the Management of Diabetes as a Cardiovascular Disease”                                                                                               Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE, Medical Director & Principal Investigator, Metabolic Institute of America, Tarzana, CA The Arthur J Lurie, MD Memorial Dinner and Keynote Presentation, sponsored by the charitable Renown Foundation and the Lurie Family, is an evening ceremony to honor and memorialize the devotion and innovation of the lake Dr. Arthur J. Lurie, who personified humanitarian, medical and community service. Dr. Lurie devoted modernized heart surgery and was steadfast in his commitment to introduce new and groundbreaking techniques cardiovascular techniques to Nevada. He promoted and inspired life-changing research and advancements in heart surgery, as well as cancer research, until his passing in 1996. Medical professionals are invited to attend the 31st Annual Trends in Cardiovascular Medicine conference will take place at the Resort at Squaw Creek in Olympic Valley, CA from Friday, Nov. 5 through Sunday, Nov. 7, 2021. Those interested in registering or learning more may visit www.renown.org/trends. The clinical team at Renown Institute for Heart and Vascular Health is the recipient of a number of national awards for outstanding clinical care and service, including: In U.S. News and World Report Best Hospital rankings for 2021, Renown Regional Medical Center - #1 in the State of Nevada for 2021. No other hospital in Nevada earned recognition from U.S. News. Renown Regional Medical Center is High Performing, its highest rating possible, for Heart Failure and Chronic Obstructive Pulmonary Disease. Awarded by the American College of Surgeons for the Renown Regional earned America's 100 Best Hospitals for Critical Care Award (2021) for Superior clinical outcomes in treating pulmonary embolism, respiratory system failure, sepsis, and diabetic emergencies. Regional also earned the Pulmonary Care Excellence Award™ (2021), for superior outcomes. Designated Level II Trauma Center. For the 30th year, Renown Regional Medical Center is northern Nevada's only designated level II trauma center. Renown Regional awarded The Get with the Guidelines - Heart Failure Gold Plus Quality Achievement award for continually ensuring heart failure patients receive the most appropriate treatment according to nationally recognized, research-based guidelines, as well as AHA's mission: Lifeline Gold Receiving honor for the treatment of patients who suffer severe heart attacks. American College of Cardiology's NCDR Chest Pain-MI Registry Platinum Performance Achievement Award. Renown Regional Medical Center is one of only 225 hospitals nationwide to receive the honor. The award recognizes Renown's success in implementing a higher standard of care for heart attack patients and signifies that Renown has reached an aggressive goal of treating these patients to standard levels of care as outlined by the American College of Cardiology/American Heart Association clinical guidelines and recommendations.  To make an appointment with a provider at Renown's Institute for Heart and Vascular Health, request that your primary care provider make a referral. For more information on Renown's Institute for Heart and Vascular Health, visit renown.org/Health-Services/Heart-Care.     About Renown Health Renown Health is a locally governed, not-for-profit integrated healthcare network serving northern Nevada, Lake Tahoe and northeast California. In U.S. News and World Report Best Hospital rankings, Renown Regional Medical Center was listed #1 in the State of Nevada. Renown has a long tradition and commitment to improve the care and the health of our community. For more information, visit renown.org.

Read More About Leading Experts Convene in Tahoe to Focus on Scientific Advancements and the Prevention of Cardiovascular Disease, the #1 Cause of Death Globally

Together, will test over 30,000 qualifying study participants by 2023 for risk of cirrhosis and liver-related illnesses. Renown Institute for Health Innovation (IHI) announced today that the organization and Gilead Sciences, Inc. will be joining forces with Siemens Healthineers to offer the Enhanced Liver Fibrosis (ELF™) Test to people with risks for nonalcoholic steatohepatitis (NASH) enrolled in the Healthy Nevada Project (HNP). The ELF Test will help identify people most at risk for progressing to cirrhosis and liver-related outcomes and allow healthcare providers to intervene before irreparable damage occurs. This noninvasive blood test uses three serum biomarkers to create an ELF score from a predefined algorithm, which can be used by doctors to help evaluate if a patient requires increased medical care and monitoring for their condition. Nonalcoholic fatty liver disease (NAFLD), which includes NASH, is prevalent in Nevada and under-diagnosed, likely affecting more than 500,000 adult Nevadans. If undetected and untreated, NASH can result in liver cirrhosis and may require liver transplantation or lead to death. There are more than 12,000 people on a waitlist for liver transplantation in the U.S. and this number continues to rise due to the increasing prevalence of NAFLD. “Thanks to important data collected through our Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study, we now know that NASH is prevalent in the state of Nevada,” said Tony Slonim, M.D., DrPH, FACHE, president and CEO of Renown Health. “We are proud to expand our partnership with Gilead and begin working with Siemens Healthineers to improve health of those with liver disease and to take early detection one step further by offering Enhanced Liver Fibrosis, ELF testing for patients of Renown Health. This test provides our team of highly-skilled physicians an advanced, noninvasive method to actively assess dynamic liver fibrosis in study participants and intervene whenever necessary, contributing to a healthier Nevada.”  “Gilead believes that noninvasive tests, including the ELF Test, will help improve the experience of people living with NASH. These tests may help to diagnose liver disease, monitor disease progression and evaluate responses to treatment without the requirement for liver biopsy,” said Rob Myers, MD, Vice President, Liver Fibrosis Clinical Research at Gilead Sciences. “The ELF Test has proven itself to be a valuable tool in NASH management and we hope this partnership will further support its use in routine care.”  “We are very pleased that NASH patients in the Healthy Nevada Project now have access to the ELF Test which offers clinically useful prognostic information for their condition with the convenience of a simple blood test. Using our advanced laboratory expertise together with Renown IHI and Gilead, we can work towards better understanding of NASH and liver disease in a representative patient population,” said Sebastian Kronmueller, Head of Molecular Diagnostics at Siemens Healthineers. “We launched the Healthy Nevada Project to help people understand more about their health, to identify serious health risks, and to give people access to innovations like the ELF Test, so they can live their best lives,” said Renown’s chief scientific officer, Dr. Joseph Grzymski, who is also a research professor at the Desert Research Institute and principal investigator of the Healthy Nevada Project. It’s incredibly rewarding to be able to report clinical findings to help our 50,000 volunteer study participants, and to assist healthcare providers in helping their patients.” The provision of the ELF Test builds on a previously announced strategic collaboration between the Renown IHI and Gilead in July 2019. This ongoing partnership aims to collect and analyze de-identified genetic and electronic health data from 60,000 qualifying study participants to enhance the understanding of NAFLD and NASH and to potentially inform development of treatment options for these diseases.  About NAFLD and NASH NAFLD is a build-up of fat in the liver of people who do not have a history of alcohol misuse. It is normal for the liver to contain some fat, but if more than 5 percent of the liver content is fat, it’s considered a fatty liver (steatosis). NASH is the most severe form of NAFLD in which a person has liver cell damage and inflammation of the liver. Inflammation and liver cell damage can cause fibrosis, or scarring of the liver, and can cause decreased liver function (1). The symptoms of NASH are often silent or non-specific, making it difficult to diagnose. About one-third of people with NASH develop cirrhosis or irreversible liver damage (2). About the ELF™ Test The ELF Test is a noninvasive blood test that can quickly identify which patients are at an elevated risk for developing cirrhosis and other liver-related clinical events (LREs). In contrast to standard liver enzyme tests that reflect liver damage that has already occurred, the ELF Test combines three serum direct biomarkers of active fibrosis. The ELF Test algorithm measures each of these biomarkers to create an ELF score, which can be used as an aid to assess the risk for future disease progression. Doctors may use this ELF score to help evaluate if a patient requires increased medical care and monitoring for their condition. Individuals interested in determining their risk for NASH and its progression are encouraged to enroll in the Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study. Those who have already consented and participated in the study will be contacted with more information on how to receive an ELF blood test. For more information or to enroll, please contact RenownIHI@renown.org or (775) 982-6914. The Enhanced Liver Fibrosis (ELF™) Test kit is not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.  In the U.S., the ELF Testing Service is available from Siemens Healthcare Laboratory, LLC (SHL), a CLIA-certified laboratory located in Berkeley, Calif. The ELF Testing Service, including the establishment of performance characteristics, was developed by SHL. The ELF Test has not been cleared or approved by the U.S. Food and Drug Administration. SHL is regulated under CLIA as qualified to perform high complexity testing. The ELF Test is used for clinical purposes and should not be regarded as investigational use only or research use only. About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Health, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information visit, renown.org. About the Renown Institute for Health Innovation Renown Institute for Health Innovation is a collaboration between Renown Health - a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute - a recognized world leader in investigating the effects of natural and human-induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at healthynv.org. Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and the Desert Research Institute established the Healthy Nevada Project (HNP), the nation’s first community-based population health study. In 2017 HNP began a partnership with Helix to leverage its population health services, Exome+™ sequencing, and consumer engagement tools. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. The HNP currently has over 60,000 participants. For more information, visit healthynv.org.  About Siemens Healthineers Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Further information is available at www.siemens-healthineers.com.Media Contact for Siemens Healthineers: Lance LongwellM: 610-448-6341E: lance.longwell@siemens-healthineers.com

Read More About Renown Institute Expands Partnership to Offer ELF Testing

Renown Health's Dr. Christopher Rowan recently joined a distinguished panel of experts on the "Game Changers in Medicine" podcast to discuss the science behind the discovery of warfarin. Renown Health Cardiologist Dr. Christopher Rowan was just featured on an episode of Game Changers in Medicine, a groundbreaking medical history podcast from Dramatic Health about some of the world’s most significant medical discoveries. The episode, Warfarin: How a rat poison became one of the world's most widely prescribed drugs, dives into the fascinating history of Warfarin and its life-saving effects on humans.  During the episode, Dr. Rowan, whose research focus is heart disease and atherosclerosis, is joined by experts Kevin Walters, Historian and Strategic Research Coordinator at the Wisconsin Alumni Research Foundation (WARF); and Ramya M. Rajagopalan, Ph.D. of the Institute for Practical Ethics at UC San Diego. Listen to the episode now or download it wherever you listen to podcasts.  History of Warfarin Warfarin prevents blood clots from forming or expanding. The drug is especially important for individuals who have experienced a heart attack or stroke, or are at risk of experiencing either. However, the backstory of the drug is rather fascinating.  Beginning in the 1920s, an unknown disease was killing cattle throughout the U.S. and Canada. Desperate to find a solution, one farmer drove 200 miles to the University of Wisconsin with a dead cow, bales of spoiled hay and a milk can of unclotted blood in tow. He crossed paths with a scientist, whose team set out to determine the hemorrhagic component of the spoiled hay, resulting in a series of medical discoveries that would revolutionize medicine.  After learning more about Warfarin and how Vitamin K could reverse its blood thinning properties, doctors first prescribed the drug for human use in 1954. It is perhaps most widely known for saving President Dwight D. Eisenhower after he suffered a heart attack in 1955. Today, Warfarin continues to saves millions of lives each year. “Before blood thinners like Warfarin, people would experience strokes, blood clots in their lungs, blood clots in their legs, blood clots in their hearts, along with countless other clotting disorders - these conditions likely cutting their lifespans short,” Dr. Rowan said during the podcast. “Warfarin revolutionized the treatment of patients who suffer from heart attacks and strokes, helping them to live normal and healthy lives. The drug changed medicine forever and helped make incredible innovations such as mechanical heart valves a reality.” Interview Opportunity Dr. Rowan is available for interviews to discuss the importance of this unique medical discovery and the positive impact it has on many of the patients he treats every day. Please email news@renown.org or call 775-691- 7308 to coordinate an interview.      About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Heath, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project® . For more information, visit renown.org. About Dramatic Health Dramatic Health, a national healthcare video company, is the producer of the six-part podcast series Game Changers in Medicine. The series premiered in July with an episode about Vitamin K and an enterprising Boston house doctor. The August episode showcased the creation of a smallpox vaccine and its parallels to today's urgent search for a COVID-19 vaccine. Game Changers in Medicine ranked #27 in Apple Podcasts: Life Sciences in the United States according to Chartable as of August 21, 2020. Both episodes, a series backgrounder, and additional material about the podcast series are available at www.gamechangersinmedicine.com and can be accessed wherever you listen to podcasts.

Read More About Renown Cardiologist Shares Insight on Warfarin

The Healthy NV Project® launches a new study to identify how private well water could impact the health of those living in the household. You use your faucet to wash your hands, make coffee and fill your water bottle. However, for approximately 41,000 people in Washoe and Churchill Counties who rely on private well water, there may be unseen contaminants present in their H2O, which could be affecting their health. The Healthy Nevada Project®, with support from the National Institutes of Health (NIH), is launching a new study to discover how private well water quality impacts the health of well owners. By providing free water testing kits to interested Healthy Nevada Project® participants, researchers will collect samples and give results back to well owners, along with resources for potential treatment options. Data from previous studies in Nevada show elevated concentrations of heavy metals in some private, household wells. Since water from household wells is not monitored for quality by government agencies, well water testing helps ensure water does not contain dangerous levels of heavy metals, such as lead, which can lead to adverse health impacts.  Those with a household well interested in receiving a free water testing kit must be enrolled in the Healthy Nevada Project’s population genetic screening study and consent to be a part of further research. People interested in joining the study can simply sign up to receive a genetic spit test kit in the mail or join the waitlist to be notified when in-person testing resumes. “The goals of the Healthy Nevada project are to improve population health and better understand processes that increase disease risks, such as cancer. In this study, we engage with our study participants and inform them about the impact of the environment on their health, while researching environmental contaminants that may elevate cancer risk,” said Joseph Grzymski, Ph.D., research professor at DRI, principal investigator of the Healthy Nevada Project® and chief scientific officer for Renown Health. “During a time where people are spending more time at home, we’re excited to launch this multi-disciplinary study that dives into possible health impacts of a household’s water source.”  “As the Healthy Nevada Project continues to serve over 54,000 research volunteers, we are proud to provide helpful information to participants, so they can make life-changing improvements to their home environment,” said Tony Slonim, M.D., DrPH, FACHE, president and CEO of Renown Health and co-director of the Healthy Nevada Project. “This allows every person with well water in Nevada, to have important information, at no charge, to help live healthier and better lives and to protect their family’s health.” The Healthy Nevada Project® is the fastest-enrolling genetic study in the country. The Project is also the first of its kind to return clinical results to study volunteers, which means participants can learn their genetic risks tied to heart disease and certain cancers, as well as lifestyle changes that could potentially help reduce their risk and prevent disease. To enroll in the Healthy Nevada Project, please visit healthynv.org.      Renown Institute for Health Innovation is a collaboration between Renown Health - a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute - a recognized world leader in investigating the effects of natural and human-induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at healthynv.org.

Read More About Could Private Well Water Unlock Health Insights?

Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000 individuals in Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and the Desert Research Institute established the Healthy Nevada Project (HNP), the nation’s first community-based population health study. In 2017 HNP began a partnership with Helix to leverage its population health services, Exome+™ sequencing, and consumer engagement tools. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. The HNP currently has 40,000 participants. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.”     About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. NASH is more common in people with certain conditions, including obesity and type 2 diabetes. There are currently limited approved treatments for patients living with NASH.   About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.   About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org.    About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Powered by their proprietary Exome+™ assay—a panel-grade exome enhanced by more than 300,000 informative non-coding regions—Helix offers health systems a scalable solution which enables the discovery of medically relevant, potentially life-saving, genetic information. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Learn more at www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC.   Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.   Additional Media Contact: Sung Lee, Investors                                                                                                                                                        650-524-7792 Arran Attridge, Media                                                                                                                                                        650-425-8975

Read More About Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)